Clinical Trial Update: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma [Phase 1]

View source ↗

Summary

Phase 1 pilot study of a genetically engineered NY-ESO-1–targeted therapy in HLA-A2+ patients with synovial sarcoma has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Synovial Sarcoma

Drugs mentioned

• NY-ESO-1 (New York esophageal squamous cell carcinoma antigen-1)
• NY-ESO-1ᶜ²⁵⁹T (NY-ESO-1–specific T cell receptor therapy)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2020-07-09